{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.372","value":"4.27"},{"groupId":"OG001","spread":"2.264","value":"4.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"MD Anderson Symptom Inventory (MDASI) Scale regularly administered during the first year following transplantation. This instrument is brief, easily understood, and provides a measure of the intensities of cancer-related symptoms. Participants rate the intensity of physical, affective, and cognitive symptoms on 0 to 10 numeric scales from \"not present\" (score of 0) to \"as bad as you can imagine\" (score of 10). Participants also rate amount of interference with daily activities caused by symptoms on 0 to 10 numeric scales from \"did not interfere\" (Score of 0) to interfered completely (score of 10).","dispersionType":"Standard Deviation","groups":[{"description":"Patients undergoing ASCT for MM who were ≥60 years old or had AL amyloidosis were randomized to receive either a standard (4-6×106 cells/kg) of CD34+ cells after melphalan 200 mg/m2.","id":"OG000","title":"Standard Dose Stem Cell Group"},{"description":"Patients undergoing ASCT for MM who were ≥60 years old or had AL amyloidosis were randomized to receive high dose (10-15×106 cells/kg) of CD34+ cells after melphalan 200 mg/m2.","id":"OG001","title":"High Dose Stem Cell Group"}],"paramType":"MEAN","populationDescription":"Intention to treat analysis, all treated participants. One participant in High Dose group did not complete adequate number of MDASI's for analysis.","reportingStatus":"POSTED","timeFrame":"The first 7 days post-transplant.","title":"Mean Symptom Severity Burden as Measured by MDASI Scores","type":"PRIMARY","unitOfMeasure":"score on a scale"}